These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37470145)

  • 1. Ruxolitinib-based regimen in children with primary hemophagocytic lymphohistiocytosis.
    Ge J; Zhang Q; Ma H; Wang D; Zhao Y; Zhu T; Wang W; Zhou C; Wei A; Lian H; Qin M; Yang J; Li Z; Wang T; Zhang R
    Haematologica; 2024 Feb; 109(2):458-465. PubMed ID: 37470145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of pediatric primary hemophagocytic lymphohistiocytosis with the HLH-94/2004 regimens and hematopoietic stem cell transplantation in China.
    Ma H; Zhang R; Zhang L; Wei A; Zhao X; Yang Y; Liu W; Li Z; Qin M; Wang T
    Ann Hematol; 2020 Oct; 99(10):2255-2263. PubMed ID: 32766934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Ruxolitinib combined with liposomal doxorubicin, etoposide, methylprednisolone+/-PEG-asparaginase in treatment of relapsed/refractory pediatric hemophagocytic lymphohistiocytosis].
    Wei A; Ma HH; Zhang LP; Lian HY; Du JY; Wang D; Cui L; Ou WX; Zhao YZ; Zhao XX; Zhang L; Li ZG; Wang TY; Zhang R
    Zhonghua Yi Xue Za Zhi; 2022 Jul; 102(28):2167-2172. PubMed ID: 35872580
    [No Abstract]   [Full Text] [Related]  

  • 4. Survival in primary hemophagocytic lymphohistiocytosis, 2016 to 2021: etoposide is better than its reputation.
    Böhm S; Wustrau K; Pachlopnik Schmid J; Prader S; Ahlmann M; Yacobovich J; Beier R; Speckmann C; Behnisch W; Ifversen M; Jordan M; Marsh R; Naumann-Bartsch N; Mauz-Körholz C; Hönig M; Schulz A; Malinowska I; Hines M; Nichols KE; Gil-Herrera J; Talano JA; Crooks B; Formankova R; Jorch N; Bakhtiar S; Kühnle I; Streiter M; Nathrath M; Russo A; Dürken M; Lang P; Lindemans C; Henter JI; Lehmberg K; Ehl S
    Blood; 2024 Mar; 143(10):872-881. PubMed ID: 37992218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of allogeneic hematopoietic stem cell transplantation for primary hemophagocytic lymphohistiocytosis in adults.
    He L; Wang Y; Suolitiken D; Zhang R; Liu M; Hua Z; Yao S; Zou H; Wang Z
    Hematol Oncol; 2022 Aug; 40(3):390-399. PubMed ID: 35526261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PEG-aspargase and DEP regimen combination therapy for refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.
    Wang J; Wang Y; Wu L; Zhang J; Lai W; Wang Z
    J Hematol Oncol; 2016 Sep; 9(1):84. PubMed ID: 27613189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic and clinical characteristics of primary hemophagocytic lymphohistiocytosis in children.
    Zhao C; Zhang Q; Zhang R; Lian H; Ma H; Zhao X; Li Z
    Ann Hematol; 2024 Jan; 103(1):17-28. PubMed ID: 37851074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. L-DEP regimen salvage therapy for paediatric patients with refractory Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis.
    Zhao Y; Li Z; Zhang L; Lian H; Ma H; Wang D; Zhao X; Zhang Q; Wang T; Zhang R
    Br J Haematol; 2020 Nov; 191(3):453-459. PubMed ID: 32525580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A study of ruxolitinib response-based stratified treatment for pediatric hemophagocytic lymphohistiocytosis.
    Zhang Q; Zhao YZ; Ma HH; Wang D; Cui L; Li WJ; Wei A; Wang CJ; Wang TY; Li ZG; Zhang R
    Blood; 2022 Jun; 139(24):3493-3504. PubMed ID: 35344583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ruxolitinib for the treatment of lymphoma-associated hemophagocytic lymphohistiocytosis: A cautionary tale.
    Trantham T; Auten J; Muluneh B; Van Deventer H
    J Oncol Pharm Pract; 2020 Jun; 26(4):1005-1008. PubMed ID: 31575356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [L-DEP regimen salvage therapy for refractory primary hemophagocytic lymphohistiocytosis triggered by Epstein-Barr virus infection in 4 children].
    Zhao YZ; Ma HH; Lian HY; Wang D; Wang TY; Zhang R
    Zhonghua Er Ke Za Zhi; 2024 May; 62(5):467-472. PubMed ID: 38623016
    [No Abstract]   [Full Text] [Related]  

  • 12. Ruxolitinib treatment for SR-aGVHD in patients with EBV-HLH undergoing allo-HSCT.
    Meng G; Wang J; Wang X; Wang Y; Wang Z
    Ann Hematol; 2020 Feb; 99(2):343-349. PubMed ID: 31879790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term effectiveness of ruxolitinib in the treatment of recurrent or refractory hemophagocytic lymphohistiocytosis in children.
    Wei A; Ma H; Li Z; Zhang L; Zhang Q; Wang D; Lian H; Zhang R; Wang T
    Int J Hematol; 2020 Oct; 112(4):568-576. PubMed ID: 32666469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ruxolitinib is an alternative to etoposide for patient with hemophagocytic lymphohistiocytosis complicated by acute renal injury: A case report.
    Yan WL; Yang SL; Zhao FY; Xu XJ
    J Oncol Pharm Pract; 2022 Jan; 28(1):222-227. PubMed ID: 34074166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and application of an LC-MS/MS method for pharmacokinetic study of ruxolitinib in children with hemophagocytic lymphohistiocytosis.
    Li Z; Sun N; Zhang Q; Ma HH; Wang D; Zhao YZ; Yang CQ; Zhang R; Zhao LB
    Anal Methods; 2022 Jun; 14(23):2293-2303. PubMed ID: 35635540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fludarabine-based reduced-intensity conditioning regimen for hematopoietic stem cell transplantation in primary hemophagocytic lymphohistiocytosis.
    Hamidieh AA; Pourpak Z; Hashemi S; Yari K; Fazlollahi MR; Movahedi M; Behfar M; Moin M; Ghavamzadeh A
    Eur J Haematol; 2014 Apr; 92(4):331-6. PubMed ID: 24330187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ruxolitinib for hematopoietic cell transplantation-associated hemophagocytic lymphohistiocytosis.
    Ono R; Ashiarai M; Hirabayashi S; Mizuki K; Hosoya Y; Yoshihara H; Ohtake J; Mori S; Manabe A; Hasegawa D
    Int J Hematol; 2021 Feb; 113(2):297-301. PubMed ID: 32979171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-escalating ruxolitinib for refractory hemophagocytic lymphohistiocytosis.
    Song Y; Li X; He X; Zhou F; Du F; Wang Z; Chen S; Wu D
    Front Immunol; 2023; 14():1211655. PubMed ID: 37457729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study.
    Bergsten E; Horne A; Aricó M; Astigarraga I; Egeler RM; Filipovich AH; Ishii E; Janka G; Ladisch S; Lehmberg K; McClain KL; Minkov M; Montgomery S; Nanduri V; Rosso D; Henter JI
    Blood; 2017 Dec; 130(25):2728-2738. PubMed ID: 28935695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of ruxolitinib in children with hemophagocytic lymphohistiocytosis: focus on the drug-drug interactions.
    Li Z; Zhang Q; He H; Sun N; Zhang R; Yang CQ; Zhao LB
    Cancer Chemother Pharmacol; 2023 Feb; 91(2):121-132. PubMed ID: 36510033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.